United Therapeutics Corp(UTHR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 6:34 PM ET (Korea 10/31 07:34)
Full metrics table
| Index | - | P/E | 21.42 | EPS (ttm) | 27.96 | Insider Own | 3.31% | Shs Outstand | 42.7M | Perf Week | 1.91% |
| Market Cap | 25.68B | Forward P/E | 19.58 | EPS next Y | 14.67% | Insider Trans | -50.16% | Shs Float | 41.5M | Perf Month | 4.78% |
| Enterprise Value | 23.02B | PEG | 2.01 | EPS next Q | 6.01 | Inst Own | 97.85% | Short Float | 5.93% | Perf Quarter | 15.96% |
| Income | 1.31B | P/S | 8.14 | EPS this Y | -4.3% | Inst Trans | -1.68% | Short Ratio | 3.44 | Perf Half Y | 4.96% |
| Sales | 3.15B | P/B | 3.99 | EPS next 5Y | 9.73% | ROA | 17.33% | Short Interest | 2.46M | Perf YTD | 22.88% |
| Book/sh | 149.97 | P/C | 9.65 | EPS past 3/5Y | 22.94% 19.27% | ROE | 19.32% | 52W High | -1.74% ($609.35) | Perf Year | 32.01% |
| Cash/sh | 62.07 | P/FCF | 23.57 | Sales past 3/5Y | 18.02% 16.5% | ROIC | 20.48% | 52W Low | 39.23% ($430.02) | Perf 3Y | 171.37% |
| Dividend Est. | - | EV/EBITDA | 15.4 | EPS Y/Y TTM | 9.29% | Gross Margin | 86.14% | Volatility(W/M) | 1.8% 3.14% | Perf 5Y | 213.86% |
| Dividend TTM | - | EV/Sales | 7.3 | Sales Y/Y TTM | 2.49% | Oper. Margin | 44.49% | ATR (14) | 17.26 | Perf 10Y | 406.79% |
| Dividend Ex-Date | - | Quick Ratio | 5.41 | EPS Q/Q | 13.46% | Profit Margin | 41.56% | RSI (14) | 70.12 | Recom | 1.53 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.73 | Sales Q/Q | -1.92% | SMA20 | 6.83% ($560.44) | Beta | 0.5 | Target Price | $670.93 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/11/4 | SMA50 | 13.59% ($527.09) | Rel Volume | 0.73 | Prev Close | $593.54 |
| Employees | 1400 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 5.95% -2.65% | SMA200 | 12.64% ($531.53) | Avg Volume(3M) | 0.71M | Price | $598.72 |
| IPO | 1999/6/17 | Option/Short | Yes/Yes | Trades | 11725 | Volume | 518,491 | Change | 0.87% |
💊 A U.S. specialty pharmaceutical company whose core asset is a treprostinil-based therapy for pulmonary arterial hypertension. It holds a portfolio of inhaled, intravenous, and oral formulations, along with an innovative pipeline that includes next-generation inhalers and implanted devices, making it a rare disease therapeutics specialist.
Over the past 1 year, on the higher side
2% below its 1-year high.
Traded less than usual. That is 73% of its average volume.
Next earnings report: November 4
3 days to go.
UTHR makes money exceptionally well
Of every $100 in sales, $44.49 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -4.3% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $1,540. Peers typically go for $1,453. Compared with its own 5-year average, it is 35% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +213.9%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 97.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #5 of 83 in the industry
Based on market cap of $26B.
HLN#3 Haleon plc ADR $38B PER 17.8 
ZTS#4 Zoetis Inc $33B PER 13.1 UTHR#5 United Therapeutics Corp $26B PER 21.4 
VTRS#6 Viatris Inc $22B PER - 
NBIX#7 Neurocrine Biosciences Inc $15B PER 21.4 
FAQ
What kind of company is UTHR?
UTHR belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of UTHR?
The market cap of UTHR is approximately $25.7B, ranking 516 within its sector.
What is the P/E ratio of UTHR?
UTHR has a P/E ratio of approximately 21.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for UTHR?
UTHR has recorded a 52-week high of $609.35 and a low of $430.02.
